Investors Raise $30 Million to Advance Quality Control for Gene Editing and Relapse Prediction for Oncology

Mission Bio announced on Dec. 13, 2018 that it has received $30 million in Series B funding from investors that include Agilent Technologies, Cota, and LAM Capital, to develop its Tapestri platform, which was first introduced in 2017. The company, a spinoff of the University of California (San FOriginal Article